{
    "id": "25316ee2-99e4-44f0-bb74-de56961ecfda",
    "indications": "jylamvo folate analog metabolic inhibitor indicated : treatment adults pediatric patients acute lymphoblastic leukemia ( ) part combination chemotherapy maintenance regimen ( 1.1 ) treatment adults mycosis fungoides ( 1.1 ) treatment adults relapsed refractory non-hodgkin lymphoma part metronomic combination regimen ( 1.1 ) treatment adults rheumatoid arthritis ( 1.2 ) treatment pediatric patients polyarticular juvenile idiopathic arthritis ( pjia ) ( 1.3 ) treatment adults severe psoriasis ( 1.4 )",
    "contraindications": "verify pregnancy status females reproductive potential starting jylamvo . ( 2.1 , 4 , 5.1 ) instruct patients caregivers take recommended directed , medication errors led deaths . ( 2.1 , 5.9 ) : recommended 20 mg/m 2 orally weekly part combination chemotherapy maintenance regimen . ( 2.2 ) mycosis fungoides : recommended 25 mg 75 mg orally weekly monotherapy ; 10 mg/m 2 orally twice weekly part combination chemotherapy . ( 2.2 ) relapsed refractory non-hodgkin lymphoma : recommended 2.5 mg orally two four times per week part metronomic combination chemotherapy . ( 2.2 ) rheumatoid arthritis : recommended starting 7.5 mg orally weekly ; adjust dose achieve optimal response . ( 2.3 ) pjia : recommended starting 10 mg/m 2 orally weekly ; adjust dose achieve optimal response . ( 2.4 ) psoriasis : recommended 10 mg 25 mg orally weekly adequate response achieved . ( 2.5 )",
    "warningsAndPrecautions": "jylamvo supplied clear yellow oral solution contains 2 mg methotrexate per ml . packaged amber type iii glass bottle tamper evident child-resistant closure ( polypropylene expanded polyethylene liner ) containing 60 ml oral solution . pack contains one bottle , low-density polyethylene ( ldpe ) bottle adaptor 10 ml white polypropylene dosing syringe ( major graduations every 1 ml minor graduations every 0.25 ml ) ( ndc 81927-204-01 ) . store jylamvo 20°c 25°c ( 68°f 77°f ) excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . storage conditions : store jylamvo room temperature 20°c 25°c ( 68°f 77°f ) . keep bottle tightly closed . first opening , discard unused medicine 3 months . jylamvo hazardous . follow applicable special handling disposal procedures.1",
    "adverseReactions": "jylamvo contraindicated : pregnant women treatment non-neoplastic diseases [ ( 5.1 ) , ( 8.1 , 8.3 ) ] . patients history severe hypersensitivity , including anaphylaxis , methotrexate [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "METHOTREXATE",
            "code": "YL5FZ2Y5U1"
        },
        {
            "name": "POLYETHYLENE GLYCOL",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "ETHYLPARABEN",
            "code": "14255EXE39"
        },
        {
            "name": "METHYLPARABEN SODIUM",
            "code": "CR6K9C2NHK"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "SHORLA ONCOLOGY INC.",
    "name": "JYLAMVO",
    "effectiveTime": "20250428",
    "indications_original": "JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis (1.4 )",
    "contraindications_original": "Verify pregnancy status in females of reproductive potential before starting JYLAMVO. ( 2.1, 4, 5.1 ) Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths. ( 2.1, 5.9 ) ALL : The recommended dosage is 20 mg/m 2 orally once weekly as a part of a combination chemotherapy maintenance regimen. ( 2.2 ) Mycosis fungoides : The recommended dosage is 25 mg to 75 mg orally once weekly as monotherapy; 10 mg/m 2 orally twice weekly as part of combination chemotherapy. ( 2.2 ) Relapsed or refractory non-Hodgkin lymphoma : The recommended dosage is 2.5 mg orally two to four times per week as part of metronomic combination chemotherapy. ( 2.2 ) Rheumatoid Arthritis : The recommended starting dosage is 7.5 mg orally once weekly; adjust dose to achieve an optimal response. ( 2.3 ) pJIA: The recommended starting dosage is 10 mg/m 2 orally once weekly; adjust dose to achieve an optimal response. ( 2.4 ) Psoriasis : The recommended dosage is 10 mg to 25 mg orally once weekly until adequate response is achieved. ( 2.5 )",
    "warningsAndPrecautions_original": "JYLAMVO is supplied as a clear yellow oral solution that contains 2 mg of methotrexate per mL. It is packaged in an amber type III glass bottle with tamper evident child-resistant closure (polypropylene with expanded polyethylene liner) containing 60 mL of oral solution.\n                  Each pack contains one bottle, a low-density polyethylene (LDPE) bottle adaptor and a 10 mL white polypropylene dosing syringe (with major graduations at every 1 mL and minor graduations at every 0.25 mL) (NDC 81927-204-01).\n                  Store JYLAMVO at 20°C to 25°C (68°F to 77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  In Use storage conditions: Store JYLAMVO at room temperature 20°C to 25°C (68°F to 77°F). Keep the bottle tightly closed. After first opening, discard any unused medicine after 3 months.\n                  JYLAMVO is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions_original": "JYLAMVO is contraindicated in:\n                  \n                     Pregnant women for treatment of non-neoplastic diseases [see Warnings and Precautions (5.1),  and Use in Specific Populations (8.1, \n                           8.3)].\n                     Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate [see Warnings and Precautions (5.2)]."
}